key: cord-1001013-sqgoab3h
authors: Byeon, Kyeong Hyang; Kim, Dong Wook; Kim, Jaiyong; Choi, Bo Youl; Choi, Boyoung; Cho, Kyu Dong
title: Factors Affecting the Survival of Early COVID-19 Patients in South Korea: An Observational Study based on the Korean National Health Insurance Big Data
date: 2021-02-26
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.02.101
sha: e1ab648911a2d206802619a4179695764a98b357
doc_id: 1001013
cord_uid: sqgoab3h

Objectives This study aims to identify the survival rate and to explore factors affecting survival among early COVID-19 patients in South Korea. Methods Data reported by the Korea Disease Control and Prevention Agency (KDCA) up to July 15, when COVID-19 was confirmed, were used as research data in connection with the National Health Insurance Service’s (NHIS) national health information database. The final analysis targets were 12,646 confirmed patients and 303 deaths. The survival rate of patients with COVID-19 was estimated through Kaplan-Meier survival analysis, Cox proportional hazard regression analysis was performed to search for factors affecting survival. Results When looking at the survival rate by age group for men and women, the 28-day survival rate for men over 80 years old was 77% and 73% for 42 days, while 83% and 81% for women. Men had a poor survival rate than women. In chronic diseases, the highest risk of mortality was observed in malignant neoplasms of the respiratory and urogenital systems, followed by diseases of the urinary system and diabetes. Conclusions The number of COVID-19 deaths was highest the next day after initial diagnosis. The case fatality rate was high in males, older age, and chronic diseases.

After the first confirmed patient of COVID-19 in Korea occurred on January 20, a sporadic outbreak occurred mostly from overseas. However, in mid-February, a religious gathering in Daegu caused a group infection by the exposure of the COVID-19 virus, and the infection spread nationwide. After that, the incidence of infected patients decreased due to the effect of social distancing policy, but the spread occurred again due to the Itaewon group infection. In Korea, the policy of distancing in daily life has been implemented, but sporadic group infections continue to occur in local communities. (Korea Disease Control and Prevention Agency, 2020) According to the data of confirmed patients from July.7.2020 to July.20.2020, in the age group, a proportion of confirmed patients was high at 41.6% among middle-aged patients in their 50s and older, and most of the deaths accounted for 50% among those aged 80 and over, which showed high fatality rate. In addition, 97.7% of the deaths were had an underlying disease. (Korea Disease Control and Prevention Agency, 2020) Prior studies have suggested that it is related to the morbidity of severe COVID-19 in patients with chronic diseases, (Rodriguez-Morales et al., 2020) , and suggested that the underlying disease may be a risk factor for severely ill patients. In addition, a lower survival rate was observed in the age of 75 or older, which was identified as a factor that increased the risk of death. (Feng et al., 2020) In sex, males had a higher case fatality rate, and the survival rate was lower in men than in females. (Alkhouli et al., 2020) , (Moon et al., 2020) Sousa et al, studies have shown that the survival rate decreases in cases of age over 60, cerebrovascular disease, diabetes, hematologic disease, neurological disease, kidney disease, etc., and these factors have been shown to affect death. (Sousa et al., 2020) Overseas studies was conducted the factors affecting the survival rate and the risk of death for various risk factors of patients diagnosed with COVID-19 through survival analysis that J o u r n a l P r e -p r o o f considers the time course from the time symptoms appeared. (Alkhouli et al., 2020 , Feng et al., 2020 , Sousa et al., 2020 On the other hand, in Korea, it was difficult to find studies related to survival analysis of COVID-19 patients considering the symptoms and the progress number of days from diagnosis to death. Therefore, this study is intended to be used as a basic data to reduce the incidence of COVID-19 as well as the risk of death through survival analysis that reflects the time until death after diagnosis of patients with COVID-19, the survival rate is identified by socioeconomic factors, chronic diseases, and explore factors that affect survival.

The purpose of this study is as followed.

Identify the survival period and epidemiological characteristics of confirmed patients with COVID-19.

Check the effect of chronic disease in patients with confirmed COVID-19 on death.

Determine the survival rate of confirmed patients with COVID-19.

To explore various factors affecting the survival of confirmed patients with COVID-19.

Data reported by the Korea Disease Control and Prevention Agency (KDCA) up to July 15, when COVID-19 was confirmed, were used as research data in connection with the National Health Insurance Service's (NHIS) national health information database.(Korea Disease Control and Prevention Agency, 2020, National Health Insurance Sharing Service, 2020) The data reported by the KDCA are patients who have been confirmed positive in a COVID-19 PCR test at public health centers and medical institutions in the reported area. These reports are epidemiological data collected by the central agency, KDCA, and created as a database. In addition, data on early COVID-19 confirmed cases in Korea were mostly collected from the outbreak in Daegu and Gyeongbuk.

J o u r n a l P r e -p r o o f Socioeconomic factor variables were extracted from the income level and death status variables reflecting gender, age, residential area, and insurance type by linking with the population table and the insurance tables of the national health information database. The variable for the presence of chronic diseases is linked to the claim data table, and a variable for the presence or absence of chronic diseases is made using the cases requested for hospitalization for more than 3 days, 4 or more outpatient visits, and 28 days or more of medication days due to principal or other diagnosis. In addition, the date of initial diagnosis of the confirmed patient was used as the start date of medical treatment if there was a claim in the confirmed patient by using the claim data of sickness details table. However, if a confirmed patient's claim does not exist, the initial diagnosis estimate date was made as follows: The first diagnostic estimation date was generated using the sequence of serial numbers and the date before and after the claim exists.

In other words, the estimated date was created only if the date without a claim was between the previous date and subsequent dates.

The most initial COVID-19 cases occurred in outbreak of Daegu and Gyeongbuk in Korea and due to the lack of beds in medical institutions, some mild patients were treated at the Community Treatment Center designated by the country. COVID-19 patients treated at the Community Treatment Center do not have the first diagnosis date because claim data does not exist. However, since Korea has a national health insurance system, it was possible to identify the socio-economic factors and chronic diseases of COVID-19 patients through claim data.

The final analysis targets were 12,646 confirmed patients linked to the corporation data from the confirmed patients reported by the KDCA, 5,356 (42.35%) males, and 7,290 (57.65%) females. The study subject's selection process is shown in the figure (Fig. 1) .

By linking the data reported by the KDCA and the national health information database, to see the difference between the general characteristics of patients confirmed to be diagnosed with J o u r n a l P r e -p r o o f COVID-19 and whether they died or not, it was analyzed through a chi-square test (χ 2 test) and suggested the crude death rate (CDR). In addition, multivariable logistic regression was performed to see chronic diseases that affect the risk of death, the odds ratio (OR), and 95% confidence interval were calculated. Lastly, the survival rate of patients with COVID-19 was estimated through Kaplan-Meier survival analysis. To search for factors affecting survival, cox proportional hazard regression analysis was performed and 95% confidence interval was calculated. Time-considered analysis was conducted in order to calculate an accurate result whether the presence or absence of chronic diseases affects the mortality hazard ratio.

All analysis was analyzed using SAS 9.4 (SAS Institute Inc., Cary. NC, USA), and the statistical significance level was expressed as a P-value of less than 0.05.

Using the difference between the estimated date of initial diagnosis and the date of death, the number of patients who died according to the elapsed date of death was the most common with 20 patients who died the next day after the initial diagnosis (Fig. 2) . The next highest number of deaths was between 3 to 11 days, which is 70% of the deaths included in the 30 th day of death. The case fatality rate was 2.97% for males, which was higher than that of females (Table   1 ). In the age group, the number of deaths was highest at age over 80 with 162 people, and the case fatality rate was highest in age group over 80 with 26.34% followed by age group of 70 to 79 with 8.93%. In region, the number of confirmed cases was the highest in metropolitan cities, and the case fatality rate was highest with 4.53% in rural area. On the other hand, the case fatality rate was the lowest in metropolitan cities. In the income level reflecting the type of insurer, the number of confirmed cases was the highest when the income level was the lowest while being an employee. The mortality rate was the highest in medical benefits, with self-J o u r n a l P r e -p r o o f employed at the highest level of income at 3.40%, and self-employed at the lowest at 3.19%.

After analyzing the comorbidities that affect the risk of death according to 298 disease classification groups, the risk of death was reviewed by grouping the chronic diseases that were statistically significant into the large and medium classification criteria (Supplementary Table   1 

When looking at the survival rate by age group for men and women, the 28-day survival rate for men over 80 years old was 77%, 75% for 35 days, and 73% for 42 days, while 83%, 82%, and 81% for women (Supplementary Table 2 , Fig 3, 4) . In city, county, and district the survival rate was low in the county, and the survival rate was low in the recipients of medical benefits in terms of income level.

J o u r n a l P r e -p r o o f Table 3 ).

In Model 2, which calibrated for socioeconomic factors and chronic diseases, the mortality hazard ratio of men was 2.25 times higher than that of women (Table 1) . As for the age group, 50-59 years old was 8.72 times, 60-69 years 19.36 times, 70-79 years 64.84 times, and 80 years old or older were 150.97 times higher than those under 49 years old. In the case of income level, when only socioeconomic factors were calibrated, the mortality hazard ratio was 1.55 times higher in medical benefits, but when socioeconomic factors and chronic diseases were calibrated, it was not statistically significant.

In Model 2, which calibrated for socioeconomic factors and chronic diseases, the following acute myocardial infarction, other ischaemic heart diseases, conduction disorders and cardiac arrhythmias, heart failure and other heart diseases 1.31 times (Table 2) .

COVID-19 can cause mild to severe symptoms and have a higher risk factor for progressing to severe condition if you are older or have an underlying disease. They are likely to require intensive treatment if they have COVID-19, and it is estimated that the duration of death that begins with infection and progresses to death will be short. Zhou F et al. A retrospective cohort study in Wuhan, China, 54 deaths were found to develop symptoms and the time to death was 18.5 days, along with 36 confirmed cases with comorbidities. In this study, among 303 deaths, the highest number of patients died within 1 day from the estimated date of initial diagnosis to death, followed by 3 to 11 days, which 50% of the deaths within 15 days were included. In the case of domestic deaths, it is necessary to explore the risk factors that cause death to reduce the number of deaths and increase the survival rate in patients with high age groups and underlying diseases because the death date is short, and most of them are accompanied by underlying diseases. Thus, this study identified the survival rate of patients with COVID-19 by socioeconomic factors and chronic diseases, and various factors that influence survival.

It was showed that the survival rate for men and women was lower in all age groups over 80, and the survival rate was lower in men than in women. In chronic diseases, the survival rate was low in patients with dementia, Parkinson's disease, Alzheimer's disease, sepsis, and malignant neoplasms of the respiratory system. In addition, the mortality hazard ratio was 2.25 J o u r n a l P r e -p r o o f times higher in men than in women, and the higher the age group, the higher the mortality hazard ratio. In this study, in order to find out the mortality hazard ratio in all age groups, the HR of the elderly age group was high because the reference was set to be under 40. In chronic diseases, the highest risk of mortality was observed in malignant neoplasms of the respiratory and urogenital systems, followed by diseases of the urinary system and diabetes.

In the Sousa et al., study, as a result of a survival analysis by age and with or without comorbidity, elderly, neurologic disease, pneumopathies, and cerebrovascular disease were found to be factors that contributed to the risk of death which is consistent with the results of this study that elderly patients and patients with co-morbidity showed a short survival period. (Sousa et al., 2020) In the results of multiple regression analysis by Moon et al., over 70 years of age, malignancy, and diabetes were contributing factors to death, which were consistent with the results of this study. (Moon et al., 2020) In the study of Lee et al., the mortality rate was high in men, in patient with diabetes, chronic lung disease, chronic neurologic disease but cancer wasn't a risk factor. Lee et al. included only 98 hospital patients age 65 and older in the study, so a sufficient number of samples were not available. However, since this study was conducted on confirmed COVID-19 patients of all ages, it is believed that there is a difference. In the study of Alkhouli et al., which looked at the gender difference in the mortality rate of COVID-19, the mortality rate of men was also high, and the survival probability before and after PSM (propensity score matching) was showed to be lower in men than in women. It is concluded that this difference cannot be fully explained as it is a higher prevalence in co-morbidity among men, which needs additional conduction of studies that stratify males and females to look at the risk of mortality due to various factors. (Alkhouli et al., 2020) In a retrospective Chinese cohort study of 26 cancer patients diagnosed with 53 .6% showed serious clinical symptoms, 28.6% of patients died, which concludes and explains the deteriorated condition and the poor prognosis, it is thought that among the J o u r n a l P r e -p r o o f chronic diseases of confirmed patients with COVID-19, cancer increases the risk of death. In this study, malignant neoplasm of the respiratory and genitourinary systems increased the HR. However, because the number of deaths for COVID-19 with cancer was small, the confidence interval was wider than that of other chronic diseases.

Previous studies have suggested that patients with severe COVID-19 have a high prevalence of diabetes. (Arentz et al., 2020 , Wang D. et al., 2020 In the Yan et al., study, the survival rate of patients with severe COVID-19 with diabetes was lower than those without diabetes, and the deaths of patients with severe COVID-19 with diabetes had a high level of inflammation (hsCRP). The large number of patients treated with mechanical ventilation treatment and intensive care unit (ICU) is thought to suggest that diabetes may be a risk factor for death in patients with COVID-19. (Yan et al., 2020) In foreign literature, a high prevalence of kidney and heart disease was observed in patients with COVID-19, and damage to the myocardium had significant association with a decrease in survival rate. As patient with myocardium damage shows high risk of death, both diseases are considered to be variables with high risk of death in patients with COVID-19. (Arentz et al., 2020 , Rodriguez-Morales et al., 2020 According to early studies in China after the outbreak of COVID-19, most deaths from COVID-19 in 2019 were adults over 60 years of age and people with serious underlying diseases. In the case of the United States, according to the results of the initial report, the mortality rate of 85 years or older was highest among the above, followed by 65 to 84 years old, and the number of hospitalizations and intensive care unit admissions was highest among 65 to 74 years old.(2020a, 2020b) In Korea, the mortality rate was 79% among those aged 70 and over of the 296 dead in COVID-19 patients, and the most severe patients was the highest in the age 70 to 79.(KCDC.) COVID-19 is a serious disease with high hospitalization, intensive care unit hospitalization, and mortality among the elderly, so it is necessary to be active in J o u r n a l P r e -p r o o f policy measures such as social distancing to slow the spread of COVID-19 and to protect elderly subjects.

The limitation of this study is: First, since the National Health Insurance Service data is a billing data, diagnosis information could only be confirmed by the disease code. The diagnosis of comorbidity in patients with COVID-19 was extracted using the conditions of hospitalization for 3 days or more, outpatient visits for 4 days or more, and medication days for 28 days or more as an annual principal or secondary diagnosis, thereby increasing the validity of the diagnosis information of the claim data. Second, if a patient is diagnosed with COVID-19, does not visit a medical institution, and goes to a living treatment center to receive treatment, the claim for treatment does not exist, so there is no treatment start date. For these patients, since the initial diagnosis date is the estimated date of the initial diagnosis made using the attempt and serial number of the reporting agency, the possibility of a slight difference from the actual diagnosis date cannot be excluded.

This study established the basis for evaluating the clinical progress of COVID-19 outbreak patients in Korea. Securing objective and more accurate initial diagnosis date information and various socioeconomic factors such as income level, death status, residential area, and chronic diseases can use by linking COVID-19 patients' report data and health insurance claim data.

Based on this, it was possible to submit more rigorous results that corrected the survival rate and factors affecting it, not a simple case fatality rate that did not take time into account. Among the confirmed cases of COVID-19, survival rates were low, and the risk of death was high in patients with high age groups and chronic diseases. Knowing the mortality rate of COVID-19 and the survival rate of patients can identify the risk factors for the occurrence of death, so it is possible to provide professional management for prevention from COVID-19, and it is expected that measures to minimize the risk of serious progression can be sought. In addition, J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f

The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China

COVID-19) -United States

Sex Differences in Case Fatality Rate of COVID-19: Insights From a Multinational Registry

Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State

COVID-19 with Different Severities: A Multicenter Study of Clinical Features

Current Status of Coronavirus Infection-19 in Korea

Risk Factors for Mortality and Respiratory Support in Elderly Patients Hospitalized with COVID-19 in Korea

Clinical characteristics and mortality predictors of COVID-19 patients hospitalized at nationally-designated treatment J o u r n a l P r e -p r o o f hospitals

Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel medicine and infectious disease

Mortality and survival of COVID-19

Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Clinical characteristics and outcomes of patients with severe covid-19 with diabetes

Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis

Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study